MARKET

OLMA

OLMA

Olema Pharmaceuticals, Inc.
NASDAQ
13.61
-0.37
-2.61%
Opening 12:41 05/13 EDT
OPEN
13.51
PREV CLOSE
13.97
HIGH
13.96
LOW
12.94
VOLUME
447.38K
TURNOVER
--
52 WEEK HIGH
36.26
52 WEEK LOW
3.890
MARKET CAP
1.19B
P/E (TTM)
-6.7185
1D
5D
1M
3M
1Y
5Y
1D
Olema Pharmaceuticals Price Target Cut to $35.00/Share From $38.00 by Guggenheim
Dow Jones · 3h ago
Olema Pharmaceuticals Is Maintained at Buy by Guggenheim
Dow Jones · 3h ago
Guggenheim Maintains Buy on Olema Pharmaceuticals, Lowers Price Target to $35
Benzinga · 3h ago
Goldman Sachs Sticks to Its Buy Rating for Olema Pharmaceuticals (OLMA)
TipRanks · 4h ago
Oppenheimer Reaffirms Their Buy Rating on Olema Pharmaceuticals (OLMA)
TipRanks · 5h ago
Olema Pharmaceuticals: Citi’s Anupam Rama Reiterates Buy on Underappreciated Palazestrant Upside and Long-Term Pipeline Catalysts
TipRanks · 6h ago
Olema Oncology price target lowered to $35 from $38 at Guggenheim
TipRanks · 6h ago
Analysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), Opus Genetics (IRD)
TipRanks · 23h ago
More
About OLMA
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. It is advancing a pipeline of novel therapies by leveraging its deep understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance. Its lead product candidate, palazestrant (OP-1250), is a proprietary, orally available complete estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD), in a Phase 3 clinical trial called OPERA-01. It is being investigated in patients with recurrent, locally advanced or metastatic ER-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In addition, it is developing OP-3136, a potent KAT6 inhibitor, in a Phase 1 clinical trial. OP-3136 is a novel, orally available small molecule that potently and selectively inhibits KAT6.

Webull offers Olema Pharmaceuticals Inc stock information, including NASDAQ: OLMA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OLMA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading OLMA stock methods without spending real money on the virtual paper trading platform.